 Shares of Chimerix NASDAQ:CMRX were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 54.29 year over year to 0.16, which beat the estimate of 0.17.Revenue of 1,402,000 declined by 2.50 from the same period last year, which beat the estimate of 1,060,000.Outlook Chimerix hasnt issued any earnings guidance for the time being.Chimerix hasnt issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on CMRXTime: 08:30 AMET Webcast URL: Action 52-week high: 3.8852-week low: 1.19Price action over last quarter: Up 17.41Company Overview Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes a treatment for acute myeloid leukemia or AML and an antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority BARDA for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment--pharmaceuticals.See more from Benzinga Recap: Momenta Pharmaceuticals Q2 Earnings Recap: Amicus Therapeutics Q2 Earnings Recap: Intercept Pharmaceuticals Q2 EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 